What is the translation of " PLATELET FUNCTION " in Slovenian?

• delovanje trombocitov
• funkcijo trombocitov

Examples of using Platelet function in English and their translations into Slovenian

Platelet function is restored within 60 minutes of stopping infusion.
Delovanje trombocitov se vzpostavi v 60 minutah po prenehanju infundiranja.

Medicinal products that inhibit serotonin uptake may lead to reduced platelet function.
Zdravila, ki zavirajo privzem serotonina, lahko zmanjšajo delovanje trombocitov.

Since iloprost inhibits platelet function its use with the following substances may enhance iloprost- mediated platelet inhibition, thereby increasing the risk of bleeding:.
Ker iloprost zavira delovanje trombocitov, lahko njegova uporaba z naslednjimi učinkovinami okrepi z iloprostom posredovano zaviranje trombocitov in tako poveča tveganje za krvavitev:.

Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.
Etorikoksib ni zaviral tvorbe prostaglandinov v želodcu in ni vplival na delovanje trombocitov.

TP plays a role in platelet function; however, therapeutic doses of laropiprant had no clinically relevant effect on bleeding time and collagen-induced platelet aggregation(see section 4.5).
TP igra vlogo pri delovanju trombocitov; vendar terapevtski odmerki laropipranta niso klinično pomembno vplivali na čas krvavitve ali agregacijo trombocitov, izzvano s kolagenom(glejte poglavje 4. 5).

Nitric oxide: since both medicinal products inhibit platelet function, their combination may in.
Dušikov oksid: ker obe zdravili zavirata trombocitno fukcijo, lahko teoretično kombinacija zdravil.

Lumiracoxib at 800 mg daily did not lead to clinically meaningful inhibition of gastric prostaglandin synthesis and had no effect on platelet function.
Lumirakoksib v odmerku 800 mg na dan ni povzročil klinično pomembne inhibicije sinteze prostaglandinov v želodcu in ni vplival na funkcijo trombocitov.

Platelet inhibition was readily reversed, with a return of platelet function towards baseline(gt; 50% platelet aggregation) 4 hours after stopping a continuous infusion of 2.0 microgram/ kg/ min.
Zaviranje trombocitov je hitro reverzibilno; 4 ure po prekinitvi kontinuirane infuzije 2, 0 mikrograma/ kg/ min se funkcija trombocitov povrne proti izhodiščni vrednosti(gt; 50% agregacija trombocitov).

Postoperative haemorrhage(P2Y12) is an inherited bleeding disorder in which platelet function is affected.
Postoperativno krvavenje(P2Y12) je dedno obolenje, ki prizdene funkcijo trombocitov in vpliva na strjevanje krvi.

Medicinal products that affect coagulation or those that alter platelet function(e.g. ticlopidine, clopidogrel, LMWH) may increase the risk of bleeding prior to, during or after tenecteplase therapy.
Zdravila, ki vplivajo na strjevanje krvi, in tista, ki spremenijo delovanje trombocitov(npr. tiklopidin, klopidogrel, nizkomolekularni heparin), lahko povečajo tveganje krvavitve pred zdravljenjem s tenekteplazo ter med njim in po njem.

Caution should be exercised if patients are required to take medicinal products that inhibit platelet function or anticoagulants.
Pri bolnikih, ki potrebujejo zdravljenje z zdravili, ki zavirajo funkcijo trombocitov ali z antikoagulanti, je potrebna previdnost.

Heparin, vitamin K antagonists and medicinal product that alter platelet function(such as acetylsalicylic acid, dipyridamole and abciximab) may increase the risk of bleeding if administered prior to, during or after reteplase therapy.
Heparin, antagonisti vitamina K in zdravila, ki spreminjajo delovanje trombocitov(kot so acetilsalicilna kislina, dipiridamol in abciksimab), lahko povečajo tveganje za krvavitev, če se jih daje pred zdravljenjem z reteplazo, med njim ali po njem.

Patients were excluded from participation in SPRYCEL clinical trials if they took medicinal products that inhibit platelet function or anticoagulants.
Bolniki, ki so jemali zdravila, ki zavirajo funkcijo trombocitov ali antikoagulante, so bili iz kliničnih preskušanj zdravila SPRYCEL izključeni.

Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function[e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, non-steroidal anti-inflammatory drugs(NSAIDs), acetylsalicylic acid(ASA)](see section 4.5) and in patients with known bleeding tendencies/disorders.
Pri bolnikih, ki jemljejo zdravila proti strjevanju krvi in/ali druga zdravila, za katere je znano, da vplivajo na delovanje trombocitov[npr. atipični antipsihotiki in fenotiazini, večina tricikličnih antidepresivov, nesteroidna protivnetna zdravila(NSAID), acetilsalicilna kislina(ASA)](glejte poglavje 4.5), ter pri bolnikih z znano nagnjenostjo h krvavitvam/motnjami krvavitev je potrebna previdnost.

If the patient requires semi-elective surgery, stop the eptifibatide infusion at an appropriate time to allow time for platelet function to return towards normal.
Če pa potrebuje polurgentno operacijo, morate infuzijo eptifibatida ustaviti dovolj zgodaj, da še omogočite normalizacijo delovanja trombocitov.

Iloprost can inhibit platelet function and its use with anticoagulants(such as heparin, coumarin-type anticoagulants) or other inhibitors of platelet aggregation(such as acetylsalicylic acid, non-steroidal anti-inflammatory medicinal products, ticlopidine, clopidogrel and glycoprotein IIb/ IIIa antagonists: abciximab, eptifibatide and tirofiban) may increase the risk of bleeding.
Iloprost lahko zavira delovanje trombocitov in njegova uporaba v kombinaciji z antikoagulanti(kot so heparin in kumarini) ali z drugimi zaviralci agregacije trombocitov(npr. acetilsalicilna kislina, nesteroidna protivnetna zdravila, tiklopidin, klopidogrel in antagonisti glikoproteinov IIb/ IIIa: abciksimab, eptifibatid in tirofiban) lahko poveča tveganje za pojav krvavitev.

Caution is advised in patients taking anticoagulants and/ or medicinal products known to affect platelet function, and in patients with known bleeding tendencies.
Pri bolnikih, ki jemljejo sredstva proti strjevanju krvi in/ ali druga zdravila, za katera je znano, da vplivajo na delovanje trombocitov, ter pri bolnikih z znano nagnjenostjo h krvavitvam je potrebna previdnost.

Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
Farmakogenetika: Pri bolnikih, ki so slabi metabolizatorji CYP2C19, med uporabo priporočenih odmerkov klopidogrela nastane manj aktivnega presnovka klopidogrela in ima manjši učinek na delovanje trombocitov.

Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function can result in the reduction of the rate of cardiovascular events such as death, myocardial infarction, or stroke.
Ker trombociti sodelujejo pri začetku in/ali razvoju trombotičnih komplikacij aterosklerotične bolezni, lahko zaviranje delovanja trombocitov vodi v zmanjšanje stopnje srčnožilnih dogodkov kot so smrt, miokardni infarkt ali možganska kap.

At the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.
Pri priporočenih odmerkih pri zdravljenju esencialne trombocitemije utegne anagrelid okrepiti učinke drugih zdravil, ki zavirajo ali spreminjajo funkcijo krvnih ploščic, npr. učinke acetilsalicilne kisline.

As expected for a prostacyclin, iloprost produced haemodynamic effects(vasodilatation, reddening of skin, hypotension, inhibition of platelet function, respiratory distress) and general signs of intoxication such as apathy, gait disturbances, and postural changes.
Kot običajno pri prostaciklinih, je iloprost povzročil hemodinamske učinke(vazodilatacijo, pordelost kože, hipotenzijo, zaviranje delovanja trombocitov, dihalno stisko) in splošne znake zastrupitve, kot so apatija, motnje ravnotežja in motnje zaradi spremembe položaja telesa.

Ticagrelor has been documented to augment the following adenosine-induced effects in healthy subjects and in patients with ACS: vasodilation(measured by coronary blood flow increases in healthy volunteers and ACS patients; headache), inhibition of platelet function(in human whole blood in vitro) and dyspnoea.
Ugotovljeno je, da ticagrelor pri zdravih osebah in bolnikih z akutnim koronarnim sindromom poveča naslednje učinke, izzvane z adenozinom: vazodilatacijo(merjeno s povečanjem koronarnega pretoka krvi pri zdravih prostovoljcih in bolnikih z akutnim koronarnim sindromom; glavobol), zavrtje delovanja trombocitov(v polni človeški krvi in vitro) in dispnejo.

Consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Posledično so trombociti, ki so bili izpostavljeni klopidogrelu, prizadeti preostanek svoje življenske dobe in okrevanje trombocitov se pojavlja s hitrostjo, ki je v skladu s trombocitno premeno.

Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan(approximately 7- 10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo(približno 7- 10 dni) in normalno delovanje trombocitov se obnovi s hitrostjo, ki je v skladu s premeno trombocitov..

Acetylsalicylic acid and clopidogrel: In a clinical study in dyslipidaemic patients receiving both acetylsalicylic acid(81 mg) and clopidogrel(75 mg), laropiprant induced transient(4 hours post-dose) inhibition of platelet function in vivo(as evaluated by bleeding time and platelet aggregation studies), but had little effect across the dosing interval.
Acetilsalicilna kislina in klopidogrel: V klinični študiji pri bolnikih z dislipidemijo, ki so prejemali acetilsalicilno kislino(81 mg) in klopidogrel(75 mg), je laropiprant povzročil prehodno(4 ure po odmerku) inhibicijo delovanja trombocitov in vivo(ocenjeno s preiskavo časa krvavitve in agregacije trombocitov), vendar pa je bil njegov vpliv med intervalom odmerjanja majhen.

Puerarin has the function of inhibiting platelet aggregation, reducing blood viscosity and promoting blood micro-cycle.
Puerarin ima funkcijo zaviranja agregacije trombocitov, zmanjšanja viskoznosti krvi in pospeševanja mikrocikla v krvi.

This period is an average and reflects the time in which the entire population is reduced platelet cyclooxygenase functioning.
To obdobje je povprečje in kaže na čas, v katerem je celotno prebivalstvo zmanjšano delovanje trombocitov ciklooksigenaze.

Your doctor may want to check your blood pressure, blood(platelet count) and the function of your kidneys.
Zdravnik bo morda preveril krvni tlak, kri(število krvnih ploščic) in delovanje vaših ledvic.

Your doctor may want to check your blood pressure, blood(platelet count) and the function of your kidney.
Zdravnik bo morda želel spremljati vaš krvni tlak, krvno sliko(število krvnih ploščic) in delovanje vaših ledvic.